Lupin could face FDA regulatory action over Tarapur API facility

13 Jan 2020

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

“The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20, 2019 as Official Action Indicated,” Lupin said in a filing to the Bombay Stock Exchange.

Lupin could face FDA regulatory action over Tarapur API facility

According to the FDA’s official definition, an OIA means that “objectional conditions were found and regulatory administrative sanctions by FDA are indicated.”

Lupin said in the filing it did not believe that the inspection classification would have an impact on disruption of supplies or the existing revenues from operations of the facility.

“The company is in the process of sending further updates of its corrective actions to the US FDA and is hopeful of a positive outcome,” Lupin said.

Back in October, the FDA issued a Form 483 listing three observations of violations of current good manufacturing practices (cGMP) at the Tarapur plant.

In the letter, the FDA said Lupin had failed to maintain batch production and control records and not carried out a satisfactory review of unexplained discrepancies “whether or not the batch has already been distributed.”

The FDA also cited failure by workers at the plant “to handle and store cleaned utensils in a manner to prevent contamination.”

Separately in another exchange filing on January 11, Lupin said the FDA had completed a Prior Approval Inspection at its Nagpur oral solid dosage manufacturing facility between January 6 and January 10, closing with 483 observations.

Lupin managing director, Nilesh Gupta said the company was committed to meeting the highest quality standards and to full compliance with current good manufacturing practice regulations at all its manufacturing facilities.

“We will address the observations raised by the agency satisfactorily and will submit our comprehensive response within the stipulated timeline,” he added.

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
The game is on for connected devices

The game is on for connected devices

20 Feb 2020

Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma.

Read more 
Management healthcare consultancy opens new offices in New York and London

Management healthcare consultancy opens new offices in New York and London

19 Feb 2020

The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.

Read more 
CPhI South East Asia rescheduled for July 2020

CPhI South East Asia rescheduled for July 2020

18 Feb 2020

Event move ensures extra precautions and safety measures taken

Read more 
Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics

Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics

18 Feb 2020

Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.

Read more 
Dr Reddy's to acquire Wockhardt divisions

Dr Reddy's to acquire Wockhardt divisions

18 Feb 2020

Deal sees 62 brands in multiple therapy areas and a manufacturing plant transfer to the company

Read more 
Sartorius sharpens its brand focus

Sartorius sharpens its brand focus

17 Feb 2020

The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.

Read more 
FDA success for MedPharm Centre of Excellence

FDA success for MedPharm Centre of Excellence

14 Feb 2020

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

Read more 
Report predicts booming ASEAN generics export market for 2020

Report predicts booming ASEAN generics export market for 2020

13 Feb 2020

The changing opportunities are attributed to rising GMP standards and increased regional harmonization.

Read more 
Partnership formed to deliver effective biopharma industry testing

Partnership formed to deliver effective biopharma industry testing

12 Feb 2020

Stevanato and Pfeiffer Vacuum will provide biopharma companies with advanced container closure integrity analysis and testing protocols.

Read more